XML 40 R25.htm IDEA: XBRL DOCUMENT
v3.8.0.1

INTANGIBLE ASSETS (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2017
Intangible Assets, Net (Excluding Goodwill) [Abstract] |
Schedule of intangible assets | The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2017 and 2016:
|  | December 31, 2017 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Amount |  |  | Weighted- Average Remaining Amortization Period (yrs.) |
Amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OPERA® software patent |  | $ | 31,951 |  |  | $ | (8,487 | ) |  | $ | 23,464 |  |  |  | 11.75 |
Development costs of corporate website |  |  | 91,743 |  |  |  | (91,743 | ) |  |  | — |  |  |  | n/a |
Approved hormone therapy drug candidate patents |  |  | 1,293,614 |  |  |  | (171,911 | ) |  |  | 1,121,703 |  |  |  | 15 |
Hormone therapy drug candidate patents (pending) |  |  | 1,721,305 |  |  |  | — |  |  |  | 1,721,305 |  |  |  | n/a |
Non-amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Multiple trademarks |  |  | 233,275 |  |  |  | — |  |  |  | 233,275 |  |  |  | indefinite |
TOTAL |  | $ | 3,371,888 |  |  | $ | (272,141 | ) |  | $ | 3,099,747 |  |  |  |  |
|  | December 31, 2016 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Amount |  |  | Weighted- Average Remaining Amortization Period (yrs.) |
Amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OPERA® software patent |  | $ | 31,951 |  |  | $ | (6,490 | ) |  | $ | 25,461 |  |  |  | 12.75 |
Development costs of corporate website |  |  | 91,743 |  |  |  | (91,743 | ) |  |  | — |  |  |  | n/a |
Approved hormone therapy drug candidate patents |  |  | 1,093,452 |  |  |  | (102,393 | ) |  |  | 991,059 |  |  |  | 16 |
Hormone therapy drug candidate patents (pending) |  |  | 1,203,987 |  |  |  | — |  |  |  | 1,203,987 |  |  |  | n/a |
Non-amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Multiple trademarks for vitamins/supplements |  |  | 185,465 |  |  |  | — |  |  |  | 185,465 |  |  |  | indefinite |
Total |  | $ | 2,606,598 |  |  | $ | (200,626 | ) |  | $ | 2,405,972 |  |  |  |  |
Schedule of estimated amortization expense | Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:
Year Ending December 31, |  |  | Estimated Amortization |
| 2018 |  |  | $ | 76,777 |
| 2019 |  |  | $ | 76,777 |
| 2020 |  |  | $ | 76,777 |
| 2021 |  |  | $ | 76,777 |
| 2022 |  |  | $ | 76,777 |
| Thereafter |  |  | $ | 761,282 |

X
- Definition Tabular disclosure of intangible assets, which may be broken down by major class. + References No definition available. + Details
Name: | txmd_ScheduleOfIntangibleAssetsTableTextBlock
Namespace Prefix: | txmd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration